Bayer’s broadly active endectocide Advocate® Spot-on (imidacloprid/moxidectin) has now received, by consensus, the positive Opinion of the Committee for Medicinal Products for Veterinary Use (CVMP) of the European Medicines Agency recommending marketing authorisation for addition of the following new therapeutic indications to the Advocate product information for cats.
• The prevention of the lungworm Aelurostrongylus abstrusus
• The treatment of the lungworm Aelurostrongylus abstrusus
• The treatment of the eye worm Thelazia callipaeda
Aelurostrongylus abstrusus remains the most important nematode affecting the cardio-respiratory system of cats worldwide, with a prevalence of 8.2% within Europe. The clinical signs in infected cats are chronic cough, sneezing, nasal discharge and dyspnoea and ranges from unnoticed mild to severe respiratory distress which can even lead to death. Cats may also show nonspecific signs such as depression, apathy, weight loss or diarrhea.
Thelazia callipaeda is a nematode which adults’ stages live under the eyelids of dogs, cats, rabbits and foxes, causing injuries with mild to severe symptoms (lacrimation, conjunctivitis and keratitis). The infective larvae are transmitted by fruit flies and adult worms are also found in humans where they are commonly known as ‘oriental eyeworm’.
Detailed conditions of the new therapeutic indications will be described in the summary of the product characteristics (SmPC), which will be published together with the European public assessment report (EPAR) after approval.